PRPF8 Antibody

What is PRPF8 and why is it important in research?

PRPF8 (PRP8 pre-mRNA processing factor 8 homolog) is a 220 kDa protein component of mammalian spliceosomes, which are large multiprotein complexes involved in removing introns from mRNA precursors . Research interest in PRPF8 has intensified due to its critical role in RNA splicing mechanisms and its involvement in diseases such as retinitis pigmentosa (RP), where mutations in PRPF8 have been identified as causative factors . The protein's function in splice site selection and exon inclusion makes it particularly relevant for investigations into post-transcriptional regulation mechanisms and disease pathogenesis.

What applications are validated for PRPF8 antibodies?

PRPF8 antibodies have been successfully employed in multiple experimental applications with published validation. Based on comprehensive testing, PRPF8 antibodies like the 11171-1-AP can be reliably used for:

• Western Blot (WB) - validated in at least 9 publications

• Immunofluorescence (IF) - validated in published research

• Immunoprecipitation (IP) - demonstrated in research literature

• Co-immunoprecipitation (CoIP) - confirmed in published applications

• RNA immunoprecipitation (RIP) - validated in research

• Immunohistochemistry (IHC) - established for tissue sections

• ELISA - applicable for protein detection

What is the appropriate dilution range for PRPF8 antibodies in different applications?

The optimal dilution of PRPF8 antibodies varies by application type and experimental system. Based on validated protocols, the following dilution ranges are recommended:

It's important to note that these ranges serve as starting points, and researchers should perform titration experiments in their specific testing systems to determine optimal concentrations .

What cell and tissue types have been validated for PRPF8 antibody detection?

PRPF8 antibodies have been validated for detection in multiple cell lines and tissue types. Specifically, positive Western blot detection has been confirmed in:

• Human cell lines: Jurkat cells, K-562 cells, and HeLa cells

• Human tissues: Placenta tissue

For immunoprecipitation, successful detection has been validated in:

• HeLa cells

For immunohistochemistry, positive detection has been confirmed in:

• Mouse brain tissue

• Human stomach cancer tissue

When designing experiments with new cell or tissue types, preliminary validation is recommended to confirm antibody performance.

How can researchers validate PRPF8 antibody specificity in their experimental systems?

To ensure antibody specificity in PRPF8 detection, researchers should implement multiple validation strategies:

• Molecular weight confirmation: Verify that the detected band corresponds to the expected molecular weight of PRPF8 (observed at approximately 220 kDa versus calculated 274 kDa)

• Positive control inclusion: Include cell lines with known PRPF8 expression (e.g., HeLa cells) as positive controls

• Knockdown/knockout validation: Conduct siRNA-mediated knockdown experiments (as demonstrated in PRPF8 depletion studies) to confirm signal reduction

• Immunoprecipitation verification: Perform IP followed by Western blot to confirm antibody specificity

• Cross-reactivity assessment: Test antibody performance across species when relevant (the antibody shows reactivity with both human and mouse samples)

How can PRPF8 antibodies be applied to investigate splicing defects in disease models?

PRPF8 antibodies serve as valuable tools for investigating splicing defects, particularly in diseases like retinitis pigmentosa. A methodological approach includes:

• Comparative analysis: Utilize PRPF8 antibodies in immunofluorescence to compare localization patterns between patient-derived and control cells

• Co-localization studies: Combine PRPF8 antibodies with other splicing factor markers to assess spliceosome assembly integrity

• Splicing complex analysis: Apply PRPF8 antibodies in co-immunoprecipitation experiments to isolate and analyze spliceosomal complexes

• Functional assessment: Correlate PRPF8 protein levels or localization with splicing events by coupling antibody-based detection with RNA-seq data analysis of alternative splicing patterns

Research has demonstrated that PRPF8 mutations alter global splicing patterns, particularly affecting alternative 3' and 5' splice sites and intron retention in retinal pigment epithelium cells from retinitis pigmentosa patients .

What methodological approaches can be used to study PRPF8's role in DNA repair using specific antibodies?

Research has identified an unexpected role for PRPF8 in DNA repair mechanisms, specifically in BRCA1-mediated homologous recombination. To investigate this function, the following methodological approach using PRPF8 antibodies is recommended:

• PRPF8 depletion and complementation:

  • Implement siRNA-mediated knockdown of PRPF8 (validated siRNAs like siPRPF8-2, siPRPF8-4)

  • Rescue experiments using expression of siRNA-resistant PRPF8 constructs

  • Verify knockdown and expression efficiency via Western blot with PRPF8 antibodies

• Functional DNA repair assays:

  • Assess homology-directed repair (HDR) efficiency

  • Evaluate single strand annealing (SSA) capacity

  • Compare with non-homologous end joining pathways to determine repair pathway specificity

• Co-localization with DNA damage markers:

  • Use PRPF8 antibodies in immunofluorescence studies following DNA damage induction

  • Assess recruitment kinetics to DNA damage sites

This approach has revealed that PRPF8 depletion causes specific defects in homology-directed repair and single strand annealing but has less impact on end joining repair pathways .

How can researchers differentiate between wild-type and mutant PRPF8 detection in patient-derived cells?

Differentiating between wild-type and mutant PRPF8 in patient-derived cells, especially for mutations that don't significantly alter protein size (such as the Val2325_Glu2331del mutation), requires sophisticated approaches:

• Allele-specific antibody development:

  • Generate antibodies targeting the specific region affected by mutation

  • For deletions like Val2325_Glu2331del, develop antibodies that recognize the junction sequence created by the deletion

• Epitope mapping:

  • Determine whether commercial PRPF8 antibodies target regions affected by the mutation

  • If the epitope includes the mutation site, differential binding may occur

• Indirect detection approaches:

  • Assess protein-protein interactions that might be disrupted by mutation

  • Study PRPF8 interactions with EFTUD2 and SNRNP200, which are known to be affected by C-terminal mutations

• Combined genomic and proteomic analysis:

  • Sequence confirmation of the mutation

  • Mass spectrometry analysis to detect peptide differences

How should researchers interpret differences between calculated and observed molecular weights for PRPF8?

When working with PRPF8 antibodies, researchers often observe a discrepancy between the calculated molecular weight (274 kDa) and the observed molecular weight on Western blots (approximately 220 kDa) . This difference requires careful interpretation:

• Post-translational modifications: Consider whether PRPF8 undergoes proteolytic processing that removes portions of the protein

• Migration anomalies: Large proteins often migrate aberrantly on SDS-PAGE due to incomplete denaturation or differential SDS binding

• Isoform detection: Determine if the antibody is detecting a specific isoform of PRPF8

• Validation strategies:

  • Use multiple antibodies targeting different epitopes of PRPF8

  • Confirm specificity through knockdown/knockout controls

  • Consider mass spectrometry analysis to confirm protein identity

The consistent detection of PRPF8 at approximately 220 kDa across multiple studies suggests this represents the authentic protein rather than non-specific binding .

What factors should researchers consider when analyzing contradictory results from different PRPF8 antibody applications?

When faced with contradictory results across different applications (e.g., positive Western blot but negative immunofluorescence), researchers should systematically evaluate:

• Epitope accessibility:

  • Different applications expose different protein epitopes

  • Fixation methods in IF/IHC may mask the antibody epitope

  • Denaturation in WB may expose epitopes hidden in native proteins

• Expression level thresholds:

  • Applications vary in detection sensitivity

  • Low PRPF8 expression may be detectable by WB but below detection limits for IF/IHC

• Technical optimization requirements:

  • Adjust antibody concentration for each application (refer to recommended dilutions)

  • Modify blocking conditions to reduce background

  • Optimize antigen retrieval methods for IHC applications

• Methodological verification:

  • Include appropriate positive controls (e.g., Jurkat cells, HeLa cells for WB)

  • Implement negative controls (secondary antibody only, isotype controls)

  • Consider alternative antibody clones targeting different epitopes

How can researchers integrate PRPF8 protein data with transcriptomic analyses of splicing changes?

To establish meaningful connections between PRPF8 protein levels/function and transcriptome-wide splicing changes:

• Correlation analysis methodology:

  • Quantify PRPF8 protein levels by Western blot or immunofluorescence

  • Perform RNA-seq with splicing-sensitive analysis (e.g., rMATS, MAJIQ)

  • Correlate PRPF8 levels with specific splicing events, particularly:

    • Alternative 3' and 5' splice sites (A3/A5)

    • Retained introns (RI)

    • Skipped exons (SE)

• Experimental design considerations:

  • Include PRPF8 knockdown/overexpression conditions

  • Compare affected versus unaffected tissues in disease models

  • Analyze cell-type specific effects (e.g., RPE versus fibroblasts)

• Functional validation:

  • Select key splicing events identified in transcriptomic analyses

  • Validate with RT-PCR to confirm splicing changes

  • Use minigene assays to directly test PRPF8's effect on specific splicing events

Research has demonstrated that PRPF8 mutations cause tissue-specific splicing alterations, with retinal pigment epithelium showing more substantial dysregulation than unaffected tissues like fibroblasts, particularly in retained intron events and alternative splice site usage .

How can researchers effectively use PRPF8 antibodies in iPSC-derived retinal models?

Induced pluripotent stem cell (iPSC) models offer valuable platforms for studying PRPF8-related retinal diseases. An effective methodological approach includes:

• Model system establishment:

  • Derive iPSCs from patients with PRPF8 mutations

  • Differentiate toward retinal pigment epithelium (RPE) cells

  • Generate isogenic controls through gene correction

  • Validate RPE identity through marker expression (CRALBP, Na+/K+ ATPase)

• PRPF8 antibody applications in iPSC-RPE models:

  • Immunofluorescence to assess PRPF8 localization and expression

  • Western blot to quantify protein levels

  • Co-immunoprecipitation to evaluate protein-protein interactions

  • ChIP-seq to investigate chromatin associations

• Functional assessments:

  • Correlate PRPF8 expression with RPE-specific functions

  • Evaluate phagocytosis capacity

  • Assess barrier function

  • Monitor cellular stress responses

Research utilizing iPSC-RPE models has revealed that PRPF8 mutations may not cause overt morphological or functional defects in early-stage cultures, suggesting that molecular changes precede visible degeneration in PRPF8-related retinitis pigmentosa .

What are the methodological considerations for using PRPF8 antibodies in multiplexed imaging approaches?

As imaging technologies advance, multiplexed detection systems offer new insights into PRPF8 function. Key methodological considerations include:

• Antibody selection for multiplexing:

  • Choose PRPF8 antibodies raised in different host species than other target antibodies

  • Verify minimal cross-reactivity between secondary antibodies

  • Consider directly conjugated primary antibodies to eliminate secondary antibody limitations

• Sequential immunostaining protocols:

  • Implement multi-round staining with antibody stripping between rounds

  • Verify that epitope detection is not compromised by previous staining cycles

  • Include controls to assess signal loss in sequential protocols

• Advanced imaging modalities:

  • Super-resolution microscopy to visualize sub-nuclear PRPF8 distribution

  • Live-cell imaging with fluorescently tagged PRPF8 to complement antibody studies

  • Proximity ligation assays to detect PRPF8 interactions with other splicing factors

• Image analysis strategies:

  • Quantitative co-localization analysis with other splicing factors

  • Nuclear speckle segmentation and intensity measurements

  • Correlation of PRPF8 distribution with splicing activity markers

How can researchers develop and validate new antibodies against specific PRPF8 domains or mutant forms?

Development of specialized PRPF8 antibodies targeting specific domains or mutations requires systematic approaches:

• Epitope selection strategies:

  • Target unique sequences within functional domains (e.g., RNase H-like domain)

  • For mutation-specific antibodies, design peptides spanning the mutation site

  • Consider epitope accessibility in native protein structure

  • Avoid highly conserved regions if species specificity is desired

• Antibody validation methodology:

  • Expression system controls: Test antibodies on overexpressed wild-type vs. mutant PRPF8

  • Knockout/knockdown validation: Confirm signal loss in PRPF8-depleted samples

  • Peptide competition assays: Verify epitope specificity

  • Cross-reactivity assessment: Test on tissues from different species

• Application-specific validation:

  • For each application (WB, IP, IF, IHC), determine optimal conditions

  • Establish appropriate positive controls

  • Document lot-to-lot consistency

  • Archive validation data for reproducibility

What strategies can resolve weak or inconsistent PRPF8 detection in Western blot applications?

When encountering difficulties with PRPF8 detection by Western blot, consider the following methodological approaches:

• Protein extraction optimization:

  • Use denaturing buffers containing strong detergents (e.g., SDS)

  • Include protease inhibitors to prevent degradation

  • Consider nuclear extraction protocols to enrich for nuclear proteins like PRPF8

• Technical adjustments:

  • Increase protein loading (30-50 μg per lane recommended for PRPF8)

  • Optimize antibody concentration within recommended range (1:500-1:2000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Employ more sensitive detection systems (enhanced chemiluminescence)

• Electrophoresis and transfer modifications:

  • Use lower percentage gels (6-8%) to better resolve high molecular weight proteins

  • Extend transfer time for large proteins like PRPF8

  • Consider semi-dry transfer systems for large proteins

• Signal enhancement approaches:

  • Implement signal amplification systems

  • Use highly sensitive substrates for detection

  • Optimize exposure time for digital imaging systems

How can researchers address background issues in immunohistochemistry with PRPF8 antibodies?

Background issues in IHC can obscure specific PRPF8 detection. A systematic troubleshooting approach includes:

• Blocking optimization:

  • Extend blocking time (1-2 hours at room temperature)

  • Evaluate different blocking agents (BSA, normal serum, commercial blockers)

  • Consider dual blocking with both protein blockers and detergents

• Antibody dilution refinement:

  • Titrate PRPF8 antibody concentration within recommended range (1:50-1:500)

  • Reduce primary antibody concentration if background persists

  • Optimize secondary antibody dilution independently

• Washing protocol enhancement:

  • Increase wash buffer volume

  • Extend washing times

  • Add detergents (0.1-0.3% Triton X-100) to wash buffers

• Tissue preparation considerations:

  • Optimize fixation time to prevent overfixation

  • Enhance antigen retrieval using TE buffer pH 9.0 as recommended

  • Consider alternative antigen retrieval methods if background persists

What approaches can improve specificity in co-immunoprecipitation experiments with PRPF8 antibodies?

Co-immunoprecipitation with PRPF8 antibodies can provide valuable insights into protein interactions but requires careful optimization:

• Lysis condition optimization:

  • Adjust detergent type and concentration to preserve protein-protein interactions

  • Test different salt concentrations to reduce non-specific binding

  • Include appropriate protease and phosphatase inhibitors

• Antibody selection and usage:

  • Follow recommended amounts for IP (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate)

  • Pre-clear lysates with appropriate control IgG

  • Consider cross-linking antibodies to beads to prevent IgG contamination

• Washing stringency balance:

  • Implement a gradient of washing stringency

  • Begin with mild washes and increase stringency

  • Monitor bead retention during washes

• Controls and validation:

  • Include IgG control immunoprecipitations

  • Perform reverse co-IPs when possible

  • Validate interactions with orthogonal methods (proximity ligation assay, FRET)

  • Consider size exclusion chromatography to validate complex formation